The Company provides a range of products in the field of resorbable biomaterials and endovascular devices in endovascular and orthopaedic markets.
The best Bull and Bear pitches based on recency and number of recommendations.
The long term growth estimate is 15 and the forward PE is only 11.64. I have a target price of over $36/share.
a negative earnings per share,coupled with a very anemic return on investment and return on equity kind of scares me with this company.
Read the most recent pitches from players about KNSY.DL.
Find the members with the highest scoring picks in KNSY.DL.
See what the Wall Street professionals think, according to their public statements and filings.